These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26550625)

  • 1. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
    Min MX; Weinberg DI; McCabe RP
    J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
    Seidman EG
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond.
    Fong SC; Blaker PA; Arenas-Hernandez M; Marinaki AM; Sanderson JD
    Biomark Med; 2015; 9(1):51-65. PubMed ID: 25605455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain.
    Egan LJ
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):170-1. PubMed ID: 17296527
    [No Abstract]   [Full Text] [Related]  

  • 8. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?
    Roberts RL; Gearry RB; Barclay ML
    Pharmacogenomics; 2010 Nov; 11(11):1505-8. PubMed ID: 21121769
    [No Abstract]   [Full Text] [Related]  

  • 9. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
    Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
    Beswick L; Friedman AB; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurines best practice.
    Friedman A
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():6-7. PubMed ID: 26990458
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A
    Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next steps on the thiopurine methyltransferase 6-thioguanine nucleotide pathway.
    Colletti RB
    J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):282-3. PubMed ID: 16954947
    [No Abstract]   [Full Text] [Related]  

  • 17. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
    Leong RW; Gearry RB; Sparrow MP
    Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
    Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
    J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.